HIV drug repurposed to fight muscle inflammation
NCT ID NCT07668505
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests whether Maraviroc, a drug currently used for HIV, can reduce muscle inflammation and improve function in adults with myositis that hasn't responded to standard treatments. Ten participants will take a daily 300mg tablet for 12 weeks and undergo muscle biopsies and function tests. The goal is to see if the drug can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Maraviroc (Selzentry, Celsentri)
What this could lead to
If it works, this could offer a new treatment option for people with myositis who haven't responded to standard therapies.
What could go wrong
This is a very small, early-phase trial with only 10 participants and no placebo group, so results may not be reliable or apply to everyone. The drug may not improve symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prince of Wales Hospital
Hong Kong, Hong Kong